LEGEND Basic Viewer
LEGEND Basic Viewer
Processing...
This web-based application provides an interactive platform to explore all analysis results generated as part of the OHDSI LEGEND study.
These results are featured in:
- Suchard MA, Schuemie MJ, Krumholz H, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB, Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet, 2019
- Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz H, Ryan PB, Schuemie MJ, Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Internal Medicine, 2019
- You, SC, Krumholz HM, Suchard MA, Schuemie MJ, Hripcsak G, Chen RJ, Shea S, Duke J, Pratt N, Reich CG, Madigan D, Ryan PB, Park RW, Park SH, Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study. Hypertension, 2021
External links
Figure 2.
Preference score distribution. The preference score is a transformation of the propensity score
that adjusts for differences in the sizes of the two treatment groups. A higher overlap indicates subjects in the
two groups were more similar in terms of their predicted probability of receiving one treatment over the other.
Figure 4.
Systematic error. Effect size estimates for the negative controls (true hazard ratio = 1)
and positive controls (true hazard ratio > 1), before and after calibration. Estimates below the diagonal dashed
lines are statistically significant (alpha = 0.05) different from the true effect size. A well-calibrated
estimator should have the true effect size within the 95 percent confidence interval 95 percent of times.
Figure 8.
Fitted null distributions per data source.